可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 颜红兵,柯元南.美国成人慢性心力衰竭诊断与治疗指南(2005年修订版)[M].北京:中国环境科学出版社,2005:7-10.
[2] McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study.The RESOLVD Pilot Study Investigators[J]. Circulation,1999,100(10):1056-1064.
[3] McMahon EG. Recent studies with eplerenone. A novel selective aldosterone receptor antagonist[J]. Curr Opin Pharmacol, 2001,1(2):190-196.
[4] Zannad F. Angiotensinconverting enzyme inhabit and spironolactone combination therapy: new objectives in congestive heart failure treatment[J]. Am J Cardiol, 1993,71(suppl):34A-39A.
[5] Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone cardiac extracellular matrix relationship[J]. Hypertension, 2001,38(5):1227-1232.
[6] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med, 1999,341(10):709-717.
[7] Pitt B, Remme W, Zannad F,et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction[J]. N Eng J Med,2003,348(14):1309-1321.
[8] Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass[J]. Lancet, 2001,357(9265):1354-1356.